John Houston, Arvinas CEO
January 10, 2023 02:24 PM EST
R&D

Arv­inas re­ports de­lay for Pfiz­er-part­nered pro­tein degra­da­tion pro­gram

Nicole DeFeudis

Editor

Arv­inas’ stock plunged about 17% on Mon­day af­ter the com­pa­ny re­vealed an­oth­er de­lay for its Pfiz­er-part­nered pro­tein de­grad­er in com­bi­na­tion with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times